Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883506 | 0.90 | ENPP2 (0.81) | ENPP2TSHRMEN1KMT2APOLB | |
| SCHEMBL4882847 | 0.90 | ENPP2 (0.66) | ENPP2TSHRKMT2AMAPTTP53 | |
| SCHEMBL4882017 | 0.85 | ENPP2 (0.60) | ENPP2TSHRMEN1KMT2AMAPT | |
| SCHEMBL14024422 | 0.84 | ENPP2 (0.58) | ENPP2TSHRMEN1KMT2APOLB | |
| SCHEMBL4878903 | 0.84 | ENPP2 (0.58) | ENPP2TSHRMEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL4880131 | 0.83 | ENPP2 (0.57) | ENPP2TSHRMEN1KMT2APOLB | |
| SCHEMBL4881088 | 0.80 | MAPT (0.73) | ENPP2TSHRMEN1KMT2APOLB | |
| SCHEMBL4883373 | 0.80 | MAPT (0.59) | ENPP2TSHRKMT2AMAPTTP53 | |
| SCHEMBL4874955 | 0.79 | ENPP2 (0.66) | ENPP2TSHRMEN1KMT2APOLB | |
| SCHEMBL4878939 | 0.79 | TSHR (0.72) | ENPP2TSHRMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1698335-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | MTNR1A, GSR, NLN | ENPP2 2226/4885TSHR 214/4885MEN1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.